Regulus to Raise $42.8M through Public Stock Offering | GenomeWeb

Regulus Therapeutics said this week that it has priced the public offering of 4.5 million shares of its common stock at $9.50 each.

As of midday Wednesday, Regulus’ stock was trading around $10.05 a share.

The company anticipates grossing $42.8 million from the offering, which is set to close around July 22. The underwriters of the offering have also been granted an option to purchase an additional 675,000 shares to cover overallotments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.